TCF19

TCF19 is a chromatin-associated transcriptional regulator that drives cell cycle progression, proliferation, and survival across multiple cell types (PMID:23860123, PMID:31746185). It reads activating chromatin marks through a PHD finger that directly binds H3K4me3, an interaction that depends on the critical residue tryptophan 316 and is required for the proliferative program controlled by a broad set of survival and proliferation genes (PMID:31746185). TCF19 occupies target promoters directly—including FOXO1-regulated loci, the TRIM14, CDKN2A, and DHX32 promoters—and thereby tunes downstream transcriptional outputs: it promotes G1/S transition by suppressing the CDK inhibitors p21, p27, and p57 while upregulating cyclin D1 via AKT/FOXO1 signaling (PMID:30509085, PMID:31141247), activates TRIM14 to engage the TBK1-IRF3-IFN-β axis (PMID:37566545), activates CDKN2A to reprogram glycolysis and macrophage polarization (PMID:40193126), and activates DHX32 to engage β-catenin signaling (PMID:39838676). TCF19 also forms a complex with p53 that recruits either CBP for activation or HDAC1 for repression to epigenetically program the metabolic genes TIGAR and SCO2 in a glucose-dependent manner, controlling cellular glycolytic and oxidative metabolism (PMID:34369624). Its own expression is controlled transcriptionally by SREBF1 binding at the TCF19 promoter (PMID:34085947). In pancreatic β-cells, loss of TCF19 arrests proliferation at the G1/S checkpoint and sensitizes cells to ER stress and apoptosis (PMID:23860123).

1. 1995 Medium

   Before any function was known, the genomic identity and structure of TCF19 had to be defined; mapping it to chromosome 6p21.3 within the MHC class I region and resolving its three-exon structure established it as a discrete gene.

   Evidence Transposon-based nested deletion sequencing and genomic mapping of a 5.5-kb fragment near HLA-C/POU5F1

   PMID:8595903

   Open questions at the time

   • No protein function, domain activity, or expression pattern established
   • No link to chromatin or transcription
2. 2013 Medium

   The first functional test asked what TCF19 does in a physiological cell type; knockdown in β-cells revealed it is required for proliferation, cell cycle progression, and protection from ER stress and apoptosis.

   Evidence siRNA knockdown in INS-1 β-cells with proliferation, flow cytometry, and qPCR readouts

   PMID:23860123

   Open questions at the time

   • Mechanism of cell cycle gene regulation not defined
   • No direct DNA or chromatin binding shown
   • Limited to a single cell line
3. 2018 Medium

   The molecular route to cell cycle control was placed on a defined signaling axis: TCF19 drives G1/S transition by inhibiting CDK inhibitors and inducing cyclin D1 through AKT/FOXO1.

   Evidence Overexpression in HCC lines with pharmacological AKT/FOXO1 inhibition and Western blot for cell cycle regulators

   PMID:30509085

   Open questions at the time

   • Did not demonstrate direct TCF19 promoter binding
   • Whether AKT/FOXO1 modulation is direct or indirect unresolved
4. 2019 High

   Two complementary studies established TCF19 as a direct chromatin reader and DNA-occupying factor: it binds H3K4me3 via its PHD finger (W316-dependent) and occupies FOXO1-regulated target loci.

   Evidence PHD finger H3K4me3 binding assay with W316 mutagenesis and genome-wide microarray in HepG2; ChIP at FOXO1 target loci in NSCLC cells

   PMID:31141247 PMID:31746185

   Open questions at the time

   • Genome-wide direct binding sites not mapped by ChIP-seq
   • How PHD reading connects to specific promoter selection unresolved
5. 2021 High

   The work expanded TCF19 into a metabolic regulator and defined a context-dependent transcriptional mechanism: TCF19/p53 complexes recruit CBP or HDAC1 depending on glucose to program TIGAR and SCO2.

   Evidence IP/MS, ChIP, luciferase reporter, and metabolic assays (OCR, ECAR, ATP, lactate) in HCC cells

   PMID:34369624

   Open questions at the time

   • What determines CBP vs HDAC1 selection mechanistically unresolved
   • Direct vs p53-dependent DNA contact of TCF19 not separated
6. 2021 Medium

   Additional findings positioned TCF19 within DNA-damage/inflammatory gene networks in β-cells and identified SREBF1 as an upstream transcriptional regulator binding the TCF19 promoter.

   Evidence Overexpression plus RNA-seq in INS-1 cells and human islets; luciferase, EMSA, and ChIP for SREBF1 at the TCF19 promoter

   PMID:34085947 PMID:34436454

   Open questions at the time

   • Direct targets of TCF19 within DDR/inflammatory networks not identified
   • Functional consequence of SREBF1-driven TCF19 expression not tested phenotypically
7. 2023 Medium

   TCF19 was linked to immune evasion through direct promoter activation: it drives TRIM14 transcription to engage the TBK1-IRF3-IFN-β axis and promote CD8+ T cell exhaustion, with therapeutic synergy alongside anti-PD-1.

   Evidence ChIP at the TRIM14 promoter, cytokine and T cell exhaustion analysis, and humanized mouse tumor models

   PMID:37566545

   Open questions at the time

   • Whether IFN-β-driven exhaustion generalizes beyond MSI endometrial cancer unknown
   • Structural basis of TCF19 promoter recognition not defined
8. 2024 Medium

   Further studies broadened TCF19's direct transcriptional targets and signaling outputs: it activates CDKN2A to reprogram glycolysis and macrophage polarization and engages RAF/MEK/ERK signaling to drive tumor growth.

   Evidence ChIP-qPCR at the CDKN2A promoter with metabolic and macrophage co-culture assays and xenografts; transcriptome and Western blot for RAF/MEK/ERK phosphorylation with shRaf1/ERK inhibitor rescue in lung cancer

   PMID:38701650 PMID:40193126

   Open questions at the time

   • How CDKN2A activation is reconciled with proliferation promotion unresolved
   • Whether RAF/MEK/ERK activation is a direct transcriptional consequence not established
9. 2025 Medium

   TCF19 was shown to directly activate DHX32 transcription to engage β-catenin signaling, with DHX32 re-expression rescuing the proliferative defect of TCF19 loss, confirming an epistatic transcriptional axis.

   Evidence ChIP-qRT-PCR and luciferase reporter at the DHX32 promoter with TCF19 knockdown/DHX32 overexpression rescue in glioma cells and xenografts

   PMID:39838676

   Open questions at the time

   • Whether DHX32 is a direct or context-specific target across tissues unknown
   • Mechanism connecting DHX32 to β-catenin not detailed

• A unified picture of how TCF19's PHD-mediated H3K4me3 reading selects among its many reported direct promoter targets, and how it switches between activation and repression complexes, remains unresolved.
• No structural model of the PHD/FHA domains in action
• No genome-wide direct binding map
• Determinants of coactivator vs corepressor recruitment unknown